Astoria Biologica

Executive Summary

Astoria Biologica is a private biotechnology company headquartered in Boston, Massachusetts, founded in 2019. The company is focused on developing novel biologics and antibody-based therapeutics for autoimmune and inflammatory diseases, with an initial emphasis on Multiple Sclerosis (MS). Leveraging its advanced biologic platforms, Astoria aims to create targeted therapies that address significant unmet medical needs in chronic inflammatory conditions. Though operating in a competitive landscape, the company's approach positions it to potentially offer differentiated treatment options. Given its early stage, Astoria has not disclosed funding rounds, valuation, or specific pipeline candidates, indicating it is likely at preclinical or early clinical development stages. The company's success will hinge on advancing its lead programs toward clinical validation and securing strategic partnerships or financing to support its R&D efforts.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Phase 1 Trial for Lead MS Candidate40% success
• Q3 2026Securing Series A Financing or Strategic Collaboration50% success
• Q2 2026Presentation of Preclinical Proof-of-Concept Data at Major Conference60% success